AI-powered analysis of brain MRI to help glioma care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project collects retrospective MRI images and clinical data from adults with glioma to train AI models. The goal is to improve non-invasive detection, tumor segmentation, and histological characterization using brain scans. Researchers will assess how AI-combined imaging features relate to tumor type, grade, and treatment decisions, with a focus on minimizing invasive procedures when possible. The study relies on previously collected records and imaging data sourced from 2019 to 2024. No experimental treatment is provided as part of the study; analyses are performed on existing data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Imaging (MRI) of confirmed glioma diagnosis in the period 2019-2024, for whom cancer types and stages, from diagnosis to post-treatment are available
* Having undergone a full brain tumor resection operation, followed or not by treatment with RT or CHT
* Adults aged 18 to 60 years
* Informed consent available, when possible and applicable

Exclusion Criteria:

* Poor quality or artifact-laden MRI images
* Lack of a minimal set of clinical information
* Explicit refusal of consent (if possible to obtain)
* Age under 18 years or over 60 years

Where it's running

• CISMed, Centre for Medical Sciences
  Trento, Italy Recruiting

Study contacts

• Study coordinator: Silvio Sarubbo, MD Spec., PhD
• Email: silvio.sarubbo@unitn.it
• Phone: + 39 0461 903487

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas

  This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.

  Recruiting at 2 sites University Hospital, Essen · Essen and 1 other locations · NCT07750457

• Connectome-guided network planning for brain tumor surgery in eloquent areas

  This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.

  Recruiting ARNAS Civico Di Cristina Benfratelli Hospital · Palermo, PA · NCT07717827

• Safusidenib in IDH1-mutant glioma after vorasidenib progression

  This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.

  Recruiting at 2 sites Phase 2 Nuvation Bio Inc. · Los Angeles, California and 11 other locations · NCT07703436

• HF1K16 with Bevacizumab for recurrent or progressive glioma

  This study tests whether HF1K16 plus Bevacizumab can help adults with recurrent or progressive glioma and whether the combo is safe.

  Recruiting Phase 2 HighField Biopharmaceuticals Corporation · Shanghai, Shanghai Municipality · NCT07678684

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.